Nature Reviews Clinical Oncology Oncology
Divarasib outperforms first-generation KRAS-G12C inhibitors in NSCLC
Abstract
Nature Reviews Clinical Oncology, Published online: 09 November 2026; doi:10.1038/s41571-026-01233-z Divarasib outperforms first-generation KRAS-G12C inhibitors in NSCLC